NasdaqCM - Delayed Quote USD

Citius Oncology, Inc. (CTOR)

Compare
1.0300 -0.1200 (-10.43%)
At close: November 4 at 4:00 PM EST

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Leonard L. Mazur Chairman, CEO & President -- -- 1945
Mr. Jaime Bartushak CFO & Treasurer -- -- 1968
Dr. Myron S. Czuczman M.D. Chief Medical Officer -- -- 1960
Mr. Myron Z. Holubiak Secretary & Director -- -- 1947

Citius Oncology, Inc.

420 Lexington Avenue
Suite 2446
New York, NY 10170
United States
347-627-0058
Sector:?
Healthcare

Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Corporate Governance

Citius Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

September 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 26, 2024 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

August 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 9, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 19, 2024 at 12:00 AM UTC

425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

July 11, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

June 18, 2024 at 12:00 AM UTC

425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

June 17, 2024 at 12:00 AM UTC

S-4/A: Offering Registrations

Related Tickers